Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aumolertinib for residual ground-glass nodules after resection of stage I EGFR-mutant lung cancer
ChiCTR2200066768Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Objective remission rate. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200066768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066768.